Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop
Martin J Coffey,1 Heleen H DeCory,2 Stephen S Lane31Pharmaceutical Product Development, Bausch and Lomb, Inc, Rochester, NY, USA; 2Global Medical Affairs, Pharmaceuticals, Bausch and Lomb, Inc, Rochester, NY, USA; 3Associated Eye Care, Stillwater, MN, USAAbstract: The eye has protective barriers (ie...
Main Authors: | Coffey MJ, DeCory HH, Lane SS |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2013-02-01
|
Series: | Clinical Ophthalmology |
Online Access: | http://www.dovepress.com/development-of-a-non-settling-gel-formulation-of-05-loteprednol-etabon-a12201 |
Similar Items
-
Formulation and evaluation of in situ ophthalmic gel of loteprednol etabonate
by: Shaikh Shoaeba, et al.
Published: (2021-06-01) -
Loteprednol etabonate (submicron) ophthalmic gel 0.38% dosed three times daily following cataract surgery: integrated analysis of two Phase III clinical studies
by: Fong R, et al.
Published: (2019-08-01) -
A retrospective analysis of the use of loteprednol etabonate ophthalmic suspension 0.5% following canaloplasty
by: Khaimi MA
Published: (2018-02-01) -
Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery
by: Timothy L Comstock, et al.
Published: (2011-02-01) -
Real-World Use of Loteprednol Etabonate 0.5%/Tobramycin 0.3% Ophthalmic Suspension for the Treatment of Ocular Surface Inflammatory Conditions
by: Deom JE, et al.
Published: (2022-11-01)